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Towards a convenient way to practice
Medical Oncology
Several organizations, groups or medical societies are currently
developing practice guidelines in oncology at a national,
regional or local level.
Clinical Practice Guidelines are defined as ‘systemically
developed statements to assist practitioner and patient
decisions about appropriate healthcare for specific clinical
circumstances’ [1].
Evidence-based Clinical Practice Guidelines are intended:
(i) to assist practitioners in appropriate clinical decision
making, (ii) to improve quality of healthcare and outcomes
for patients and (iii) to influence national policies for efficient
allocation of resources and for better delivery systems [2]. In
other words, to provide the right care, at the right time, for
the right person in the right way [3].
Despite some negative clinician attitudes to clinical
guidelines, it is universally accepted that most practitioners are
supportive of guidelines. In a recently published systematic
review survey of clinician attitudes towards clinical practice
guidelines (including various medical or surgical specialties
worldwide), 70%–75% of clinicians agreed that guidelines are
helpful sources of advice, good educational tools and intended
to improve quality. However, 30%–52.8% of them also
considered that guidelines are impractical and too rigid to
apply to individual patients, they reduce physician autonomy,
they oversimplify medicine, they would increase litigation
and they are intended to cut healthcare costs [4].
In another national survey of Canadian oncologists’ attitudes
towards practice guidelines, >80% of the respondents agreed
that they were good educational tools, convenient sources of
advice and intended to improve quality of care. Conversely, 42%
felt they were intended to cut costs, 26% were oversimplified
‘cookbook’ medicine, 20% were rigid to apply to individual
patients and 16% were a challenge to physician’s authority.
Nevertheless, Canadian oncologists were quite positive about
practice guidelines and reported using them frequently [5].
The European Society for Medical Oncology (ESMO) is
continuing the development and dissemination of Clinical
Recommendations to all European and non-European
Oncologists.
The ESMO motivation was to establish Guidelines which
will be important for the future development of Medical
Oncology and for achieving high common standards of medical
practice for patients in all European countries.
The original idea for the creation of ESMO Clinical
Guidelines came through the Central European Task Force in
1998 by Prof H. Hansen. Particularly, he visualized the need
for such clinical recommendations which might be more
practical in daily use.
Thus, in 1999 the ESMO Guidelines Task Force was
constituted. Initially, the group began with a Chairman
(R. Stahel—Switzerland), a Central Coordinator
(L. Jost—Switzerland), an ESMO Officer (M. C. Reinhart) and
five members (J. Herrstedt—Denmark, O. Kloke—Germany,
N. Pavlidis—Greece, G. Purkalne—Latvia and S.
Jelic—Yugoslavia). During the next 5 years, more members
joined the Task Force (J. Bergh—Sweden, R. Greil—Austria,
V. Kataja—Finland and J. Olivera—Portugal).
The clinical recommendations are an important expression of
ESMO’s mission to disseminate knowledge, in order to
maintain a high common standard in medical practice for
cancer patients. First, the guidelines are a tool for clinicians
to help them offer the best care to their patients on a daily
basis. They also help support negotiations with politicians,
administrators and insurance companies regarding the level of
care that should be made available.
The principles of ESMO Guidelines were: (i) to create a set
of statements for basic standard of care in no more than
three-page format, (ii) to be disease or topic oriented, (iii) to
be evidence based, (iv) to have emphasis on medical oncology
and (v) to be regularly updated.
Each of the ESMO Clinical Recommendations
provides vital, evidence-based information for physicians,
including the incidence of the malignancy, diagnostic criteria,
staging of disease and risk assessment, treatment plans and
follow-up.
Since, 1 January 2006 the Guidelines Task Force became an
independent group—the ESMO Guidelines Working
Group—under the new ESMO Education Committee structure.
It constitutes: (i) of an Editorial Board with a Chairman
(N. Pavlidis—Greece), three members (R. Stahel—Switzerland,
H. Hansen—Denmark, S. Jelic—Serbia) an Annals of Oncology
executive (L. Rowett—UK) and an ESMO Officer
(P. Minotti—Switzerland), (ii) of seven Subject Editors
responsible for the topics, the authors, the revision of the
manuscripts and the presentation and discussion of final drafts
with the Editorial Board (M. Castiglione—Switzerland, J.
Oliveira—Portugal, E. Felip—Spain, V. Kataja—Finland, M.
Dreyling—Germany, L. Jost—Switzerland, F. Roila—Italy),
(iii) of assigned Authors and (iv) of five preselected Reviewers
per topic all been ESMO Faculty Members (Figure 1).
Nearly 7 years after the inception of ESMO Guidelines Task
Force and up to the end of 2006, 39 Clinical Recommendations
will be freely available on the ESMO Web site (www.esmo.org/
reference/reference-guidelines.htm) and in Annals of Oncology.
The future intention is to cover most of malignant tumors or
other topics in Oncology.
The current activities of ESMO Guidelines Group
include: (i) generation of yearly updates and new guidelines
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through an on-line process, (ii) yearly publications of ESMO
Clinical Recommendations as supplement to the Annals of
Oncology, (iii) interactive guideline sessions at ESMO
Congresses and (iv) promotion of ESMO Clinical
Recommendations.
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Levels of evidence [I–V] and grades of recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts
and the ESMO faculty.
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Figure 1. The new structure of the ESMO Clinical Recommendations
Group.
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